Metabolite identification of liguzinediol in dogs by ultra-flow liquid chromatography/tandem mass spectrometry

• Liguzinediol, 2,5-dihydroxymethyl-3,6-dimethylpyrazine, is a novel derivative of ligustrazine with lower side effect and good pharmacokinetics profiles.
• Seven metabolites of liguzinediol in Beagle dogs were detected and identified by UFLC/Q-TOF MS.
• The main metabolism pathways included oxidation, sulfation, cysteine conjugation (glutathione conjugation) and glucuronidation.

Ultra-flow liquid chromatography/quadrupole-time-of-flight mass spectrometry (UFLC/Q-TOF MS) method combined with metabolitepilotMT software was used for analysis of the metabolites of liguzinediol in dogs. Urine, bile, feces and plasma samples were collected after intravenous administration of 8 mg/kg liguzinediol to healthy dogs. Besides liguzinediol, seven metabolites were detected and identified by UFLC/Q-TOF MS method. The results showed that liguzinediol had some main metabolic pathways in dogs including oxidation, sulfation, cysteine conjugation, N-acetylcysteine conjugation and glucuronidation.